A liquid crystal nanostructure, used as vaccine platform, modifies biodistribution of vaccine components

CONSTANZA MARIN, , I, M. ,; MARIA FERNANDA SANCHEZ VALLECILLO; ANA L. CHIODETTI; SANTIAGO D. PALMA,; GABRIEL MORÓN, ; DANIEL A. ALLEMANDI; CRISTINA PISTORESI PALENCIA; BELKYS A. MALETTO.

Buenos Aires

Congreso; Reunión conjunta de Sociedades de Biociencias; 2017

SAFE

In the last years much effort in vaccinology has focused on the new formulation strategies for subunit vaccines. We formulated OVA (antigen) and CpG-ODN (TLR-9 agonist) with a nanostructure formed by self-assembly of 6-O-ascorbyl palmitate (Coa-ASC16). We have previously shown that this nanovaccine (OVA/CpG-ODN/CoaASC16) elicited an adaptive immune response superior to those induced by an aqueous formulation (OVA/CpG-ODN). However, we still do not know exactly the mechanisms of action of Coa-ASC16. Hence, the aim of this work was to test the impact of this nanoformulation on biodistribution of vaccine components and early immune response. Methods: mice were s.c. immunized with OVA/CpG-ODN or OVA/CpG-ODN/Coa-ASC16. OVA and CpG-ODN were labeled with near-infrared fluorescent dye, and both signals were measured with an Odyssey® CLx at several time points post immunization (pi). Cytokines/chemokines were evaluated in plasma by a multiplex assay at 1.5h pi. Results are indicated as OVA/CpG-ODN vs OVA/ CpG-ODN/Coa-ASC16. Liver: OVA signal was 1.2 x 107 vs 0.6 x 107 (p